These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484 [TBL] [Abstract][Full Text] [Related]
24. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Nurden AT; Viallard JF; Nurden P Lancet; 2009 May; 373(9674):1562-9. PubMed ID: 19324405 [TBL] [Abstract][Full Text] [Related]
25. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option. Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333 [TBL] [Abstract][Full Text] [Related]
26. Eltrombopag in thrombocytopenia. Lawson A N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18322290 [No Abstract] [Full Text] [Related]
27. Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. Koehrer S; Keating MJ; Wierda WG Leukemia; 2010 May; 24(5):1096-8. PubMed ID: 20339441 [No Abstract] [Full Text] [Related]
28. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag. Tarantino MD; Fogarty PF; Shah P; Brainsky A Platelets; 2015; 26(1):93-6. PubMed ID: 24433306 [TBL] [Abstract][Full Text] [Related]
29. New therapy options for chronic immune thrombocytopenic purpura: a breath of fresh air. Introduction. Francesco R Eur J Haematol Suppl; 2009 Mar; (71):1-2. PubMed ID: 19200300 [No Abstract] [Full Text] [Related]
30. [Eltrombopag increases thrombocyte count and reduces the bleeding risk]. Med Monatsschr Pharm; 2007 Oct; 30(10):390-1. PubMed ID: 17966290 [No Abstract] [Full Text] [Related]
31. Eltrombopag in chronic idiopathic thrombocytopenic purpura. Panzer S; Pabinger I Lancet; 2009 Feb; 373(9664):607-8. PubMed ID: 19231614 [No Abstract] [Full Text] [Related]
33. Eltrombopag for use in children with immune thrombocytopenia. Kim TO; Despotovic J; Lambert MP Blood Adv; 2018 Feb; 2(4):454-461. PubMed ID: 29487060 [TBL] [Abstract][Full Text] [Related]
34. Thrombopoietin-receptor agonist as a treatment of thrombocytopenia associated with systemic lupus erythematosus. Moreno Martínez MJ; Gallego P; Moreno Ramos MJ Reumatol Clin; 2016; 12(1):57. PubMed ID: 26024588 [No Abstract] [Full Text] [Related]
35. [Management of refractory ITP with thrombopoietin receptor agonists]. Tomiyama Y Rinsho Ketsueki; 2011 Aug; 52(8):627-32. PubMed ID: 21897068 [No Abstract] [Full Text] [Related]
36. Molecule of the month. Eltrombopag. Drug News Perspect; 2008; 21(6):344. PubMed ID: 18836592 [No Abstract] [Full Text] [Related]
37. [Trombopag for chronic immune thrombocytopenia in a patient previously treated with romiplostim]. Rodríguez Vargas B; Serna Pérez J; Bermejo Vicedo T Farm Hosp; 2013; 37(3):265-6. PubMed ID: 23789804 [No Abstract] [Full Text] [Related]
38. Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia. Lambert MP; Witmer CM; Kwiatkowski JL Am J Hematol; 2017 Jun; 92(6):E88-E91. PubMed ID: 28240793 [No Abstract] [Full Text] [Related]
39. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia. Haselboeck J; Kaider A; Pabinger I; Panzer S Thromb Haemost; 2013 Apr; 109(4):676-83. PubMed ID: 23389750 [TBL] [Abstract][Full Text] [Related]
40. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists. Ghanima W; Lee SY; Barsam S; Miller A; Sandset PM; Bussel JB Br J Haematol; 2012 Sep; 158(6):811-4. PubMed ID: 22816787 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]